[Lactic dehydrogenase activity in pleural fluid].
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to C Verrastro.
Explore the source record for details and available documents.
The role of the concurrent use of theophylline and beta-adrenergic agents for relief of bronchial obstruction is controversial. For this reason, we studied the lung function of 9 patients with chronic obstructive pulmonary disease, whose ages ranged from 51 to 69 (average 60.6 +/- 6.6) years, after the oral administration of theophylline and theophylline plus salbutamol. After withdrawal of all bronchodilators for 24 hours, the basal values of forced vital capacity (FVC) and forced expiratory volume in one second (FEV1) were obtained. Oral slow release theophylline (600 mg/day) was then administered for 7 days, followed by 7 days of the concurrent use of the same dose of theophylline plus salbutamol (16 mg/day). Spirometry was reevaluated at the end of each week. Pretreatment FVC ranged from 0.85 to 2.57 (average 1.78 +/- 0.64) liters, FEV1 from 0.70 to 1.64 (average 1.15 +/- 0.30) liters and theophylline serum levels from 0.1 to 3.1 (average 1.81 +/- 1.01) micrograms/ml. At the end of the first week, FVC was 1.38 to 3.26 (average 2.03 +/- 0.65) liters, FEV1 0.85 to 1.73 (average, 1.40 +/- 0.29) liters and theophylline serum levels 8.1 to 21.0 (average 13.40 +/- 4.18) micrograms/ml. With the concurrent use of theophylline and salbutamol FVC ranged from 1.24 to 2.57 (average 1.90 +/- 0.50) liters and FEV1 from 0.96 to 1.90 (average 1.46 +/- 0.33) liters, values not statistically different from theophylline alone.
Several drugs interfere with theophylline pharmacokinetics, inducing changes on it's serum levels. With the purpose of determining a possible influence of oral administered beta-2-adrenergics agents on theophylline serum levels ten patients with bronchial obstruction, whose ages ranged from 51 to 69 (average 59.90 +/- 6.67) years, were analysed. After a period of 24 hours without any medication, the patients received 600 mg of oral slow release theophylline per day, for 7 days, followed by 7 days of the same dose of theophylline combined with 16 mg of oral salbutamol. Blood samples were drawn after the 24 hours without medication and at the 4th hour after the morning dose of theophylline, at the end of each week. The serum levels were, respectively, 2.08 +/- 1.20 micrograms/ml, 15.18 +/- 6.87 micrograms/ml and 11.45 +/- 5.15 micrograms/ml. The levels of the phase (theophylline alone) were significantly higher than those obtained after the concurrent use of theophylline and salbutamol. It can be concluded that this association interferes on theophylline pharmacokinetics. We suggest that in patients taking these drugs the serum levels of theophylline shall be measured to permit an eventual correction of the dose of theophylline being administered.
Pulmonary alveolar proteinosis is a rare disease characterized by the filling of the alveolar spaces of the lung by a PAS-positive lipoproteinaceous material. Despite the clear characterization of this material, the etiopathogenesis of the disease remains obscure. We present four patients who were admitted in our Department over the last seven years. The diagnosis was confirmed by lung biopsy in all cases. Three patients improved after bronchoalveolar lavage. Spontaneous remission was observed in one case.
Explore the source record for details and available documents.